<i>Neisseria</i> species on the tonsillar surface predicts favorable clinical outcomes in patients with Immunoglobulin A nephropathy who underwent tonsillectomy حسب Ryosuke Sato (615801)

"…<p>An aberrant mucosal immune response against commensal bacteria in the tonsils is hypothesized to be one of the pathogenic mechanisms underlying immunoglobulin A nephropathy (IgAN). However, the bacteria involved in the pathogenesis of IgAN have not been fully elucidated. …"

Agreement between microscopy and qPCR analysis of MarBTN progression. حسب Rachael M. Giersch (22331947)

Detection of MarBTN-specific eDNA in tank water at late stages of MarBTN progression. حسب Rachael M. Giersch (22331947)

MarBTN-specific eDNA detection in each clam that was followed for MarBTN in hemolymph and eDNA. حسب Rachael M. Giersch (22331947)

Modeling the relationship between cancer level in hemolymph and MarBTN in tank eDNA. حسب Rachael M. Giersch (22331947)

Comparison of postoperative rest and activity between APS score groups in Experiment 2. حسب Akihiro Ohnishi (10989900)

The observed MRM reactions. حسب Ewa Paszkowska (21246702)

"…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …"

Intra- and inter-day precision and accuracy. حسب Ewa Paszkowska (21246702)

"…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …"

Survival of soft-shell clams with MarBTN compared to control clams. حسب Rachael M. Giersch (22331947)

"…(<i>B</i>) Analysis of long-term non-progressing clams (n = 11, light red line), along with their respective paired controls (blue line), shows no difference in survival with maintained low-level infection. (C) A sub-analysis of low-positive clams in which MarBTN progressed and did not regress (n = 9, dark red line), with survival starting at the time the clam was detected with >10% cancer, compared with their paired control clams starting at the same date (blue line), shows a significant decrease in time-to death. “+” marks the dates at which two negative control animals were culled before natural death (these events were censored in the survival analysis).…"

Comparison of sleep and activity the night before and after surgery in Experiment 1. حسب Akihiro Ohnishi (10989900)

Mod is required to maintain nucleolar architecture. حسب Amalia S. Parra (4173004)

Development of <i>Drosophila</i> Neuroblasts (NB). حسب Amalia S. Parra (4173004)

RNA targets of Mod identified by RiP-Seq. حسب Amalia S. Parra (4173004)

"…Mod is expressed in larval brains and its loss leads to a significant decrease in the number of central brain NBs. …"

Data for Fig 1. حسب Rachael M. Giersch (22331947)

"…We observed variable outcomes, with about half of clams (9/21) progressing to high levels of cancer and death, about half exhibiting long-term non-progression (11/21), and a single animal showing regression of cancer. We also observe a significant decrease in survival in animals that progress to >10% cancer in their hemolymph, while we see no effect on survival in clams with BTN that are long-term non-progressors. …"

Changepoint analysis in comparison of MarBTN-specific eDNA and cancer in hemolymph. حسب Rachael M. Giersch (22331947)

S1 Data - حسب Richard Junior Zapata Dongo (17912565)

"…This interaction was further supported by a significant decrease of ALK phosphorylation in single and combination treatment with 300nM ABT-199. …"

Loss of Mod does not affect NB asymmetric cell division. حسب Amalia S. Parra (4173004)

Negative (Prednisone) and basal (ATP) control compounds binding to ALK protein. حسب Richard Junior Zapata Dongo (17912565)

Mod localizes both within and outside the nucleolus in NBs. حسب Amalia S. Parra (4173004)

Mod is expressed throughout the larval CNS and is primarily nuclear. حسب Amalia S. Parra (4173004)